In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily ...

An external data and safety monitoring committee conducted regular safety monitoring. All patients received lenvatinib 20 mg orally once daily and ≤ 35 doses of pembrolizumab 200 mg intravenously once ...